GSK3235025 is a potent and selective inhibitor of the deubiquitinating enzyme USP7 (ubiquitin-specific protease 7), primarily utilized in medical research and drug development for oncology. USP7 plays a key role in regulating protein stability and cellular processes involved in cancer cell proliferation, survival, and DNA damage response. Researchers use this compound to investigate its efficacy in targeting USP7-dependent pathways that promote tumor growth, such as those involving p53 and MDM2, making it a valuable tool in preclinical studies across various cancer types. Its applications include exploring mechanisms of action, evaluating potential synergies with other therapies, and serving as a lead compound for optimization in biochemical assays and oncology drug discovery.